CYTOKINETICS INC

For the period ended Dec 31, 2025. Filed Feb 26, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 26, 2026

CYTK$56.18+1.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except per share data)

	Years Ended December 31,
	2025	2024	2023
Revenues:
Collaboration revenues	$8,686	$3,474	$4,030
License and milestone revenues	79,353	15,000	3,500
Total revenues	88,039	18,474	7,530
Operating expenses:
Research and development	416,026	339,408	330,123
General and administrative	284,271	215,314	173,612
Total operating expenses	700,297	554,722	503,735
Operating loss	(612,258)	(536,248)	(496,205)
Interest expense	(45,579)	(37,701)	(28,306)
Non-cash interest expense on liabilities related to revenue participation right purchase agreements	(58,289)	(48,811)	(29,362)
Interest and other income, net	48,420	51,534	27,629
Change in fair value of derivative liabilities	4,200	1,300	—
Change in fair value of liabilities related to RPI Transactions	(200)	(19,600)	—
Debt conversion expense	(121,249)	—	—
Net loss	$(784,955)	$(589,526)	$(526,244)
Net loss per share — basic and diluted	$(6.54)	$(5.26)	$(5.45)
Weighted-average number of shares used in computing net loss per share — basic and diluted	120,103	111,979	96,524
Other comprehensive (loss) gain:
Unrealized (loss) gain on available-for-sale securities, net	(990)	2,153	3,600
Foreign currency translation adjustments	(778)	255	(20)
Comprehensive loss	$(786,723)	$(587,118)	$(522,664)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.